Crosstex expands product portfolio by acquiring Sterilex Liquid Ultra
Crosstex expanded its infection prevention and compliance portfolio with the acquisition of the Sterilex Liquid Ultra product from Sterilex Corp.
Crosstex expanded its infection prevention and compliance portfolio with the acquisition of the Sterilex Liquid Ultra product from Sterilex Corp. Sterilex Liquid Ultra is a proprietary product developed for the treatment of dental unit waterlines. The product was specifically developed to penetrate and remove biofilms from dental unit waterlines, to kill biofilm bacteria and to disinfect the interior surfaces.
Sterilex Liquid Ultra is the first and only product to be granted the following claims by the U.S. EPA: removes biofilm from dental unit waterlines; prevents and suppresses formation of biofilm in dental unit waterlines, kills biofilm bacteria and maintains dental unit waterline effluent water at less than 500 CFU/mL.
“With the addition of Sterilex Liquid Ultra to our product portfolio, Crosstex is now the market leader in the dental waterline product category” states Andrew Whitehead, Crosstex Senior Vice President of Business Development.
Gary Steinberg, president and CEO of Crosstex added, “Dental unit waterline disinfection continues to be one of the fastest growing market segments in the dental industry. As with our DentaPure acquisition last year, Sterilex Liquid Ultra has an equally strong market position with their unique and innovative proprietary technology that provides a strategic benefit to our overall waterline treatment business.”
A division of Cantel Medical, Crosstex manufactures a wide array of infection prevention and compliance products for the global healthcare industry. The company’s headquarters is in Hauppauge, N.Y.